Gerasimos S Filippatos
Inserm
4 papers in the Anchorcite directory, published between 2010 and 2021, cited 23,071 times in total.
ORCID profileResearch topics
- Atrial Fibrillation Management and Outcomes · 2 papers
- Diabetes Treatment and Management · 2 papers
- Heart Failure Treatment and Management · 2 papers
- Cardiac pacing and defibrillation studies · 1 paper
- Cardiovascular and Diving-Related Complications · 1 paper
- Acute Ischemic Stroke Management · 1 paper
Frequent co-authors
- Piotr P. Ponikowski · 4 papers
- Paulus F. Kirchhof · 2 papers
- Dan Atar · 2 papers
- Hein Heidbüchel · 2 papers
- Gerhard Hindricks · 2 papers
- Bogdan Alexandru Popescu · 2 papers
- Ulrich Schotten · 2 papers
- A. John Camm · 2 papers
Papers
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTSEP Europace · 2016 · 6,438 citations
2 Representing the European Stroke Association (ESO) ESC Committee for Practice Guidelines (CPG) and National Cardiac Societies Reviewers can be found in the Appendix.ESC entities having participated in the development of this document: Associations: European Association for Cardiovascular Prevention and…
- Guidelines for the management of atrial fibrillationEuropean Heart Journal · 2010 · 5,954 citations
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, occurring in 1–2% of the general population. Over 6 million Europeans suffer from this arrhythmia, and its prevalence is estimated to at least double in the next 50 years as…
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureNew England Journal of Medicine · 2020 · 5,468 citations
BACKGROUNDSodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes.More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart…
- Empagliflozin in Heart Failure with a Preserved Ejection FractionNew England Journal of Medicine · 2021 · 5,211 citations
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. METHODS: In…
Metadata from OpenAlex (CC0).